Compare HYPR & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYPR | ICCC |
|---|---|---|
| Founded | 2014 | 1982 |
| Country | United States | United States |
| Employees | 102 | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.2M | 93.1M |
| IPO Year | 2021 | 1995 |
| Metric | HYPR | ICCC |
|---|---|---|
| Price | $0.78 | $10.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $1.59 | N/A |
| AVG Volume (30 Days) | ★ 368.3K | 14.7K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.21 | ★ 53.85 |
| EPS | N/A | ★ 0.41 |
| Revenue | $13,563,000.00 | ★ $26,493,169.00 |
| Revenue This Year | $50.75 | N/A |
| Revenue Next Year | $29.71 | N/A |
| P/E Ratio | ★ N/A | $24.29 |
| Revenue Growth | 5.22 | ★ 51.64 |
| 52 Week Low | $0.76 | $4.52 |
| 52 Week High | $2.22 | $12.10 |
| Indicator | HYPR | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 33.22 | 47.04 |
| Support Level | N/A | $9.27 |
| Resistance Level | $1.39 | $10.75 |
| Average True Range (ATR) | 0.03 | 0.26 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 33.33 | 66.43 |
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.